Sima Ferman

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

Gianni Bisogno, Gian Luca De Salvo, Christophe Bergeron et al. · The Lancet Oncology · 2019 · 240 citations · Full text

Medicine, Oncology, Pharmacology +12

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

Gianni Bisogno, Meriel Jenney, Christophe Bergeron et al. · The Lancet Oncology · 2018 · 185 citations

Medicine, Oncology, Pharmacology +13

Cancer incidence among children and adolescents in Brazil: First report of 14 population‐based cancer registries

Beatriz de Camargo, Marceli de Oliveira Santos, Marise Souto Rebelo et al. · International Journal of Cancer · 2009 · 157 citations

Medicine, Oncology, Pediatrics +15

Fusion status in patients with lymph node‐positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Soledad Gallego, Ilaria Zanetti, Daniel Orbach et al. · Cancer · 2018 · 84 citations · Full text

Medicine, Oncology, Surgery +14

Mitotane Associated With Cisplatin, Etoposide, and Doxorubicin in Advanced Childhood Adrenocortical Carcinoma

Patrícia Zancanella, Mara Albonei Dudeque Pianovski, Brás Heleno de Oliveira et al. · Journal of Pediatric Hematology/Oncology · 2006 · 72 citations

Medicine, Oncology, Pharmacology +16